
Overview
Alpha Pharmaceutical provides international business consulting for pharmaceutical companies. Its services include market research in EU countries, support with negotiations and manufacturer agreements, registration of medicines, medical devices and supplements, and sales of medicines and APIs.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $4,670 |
Filing timeliness
Financial statements were filed on time, on average 102 days early.
- 202502/06/2026
- 202418/03/2025
- 202315/03/2024
- 202213/03/2023
- 202104/04/2022
- 202006/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Trademarks
The company holds 4 active trademarks registered with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2020.
| Mark | Protected until | |
|---|---|---|
| LYDEN (word) | Jun 4, 2030 | |
| SOLISTA (word) | Jun 4, 2030 | |
| SLANDIX (word) | Jun 4, 2030 | |
| Mark without a word element (figurative) | Feb 28, 2030 | |
| ALPHA PHARMACEUTICAL (word) | – |
Authorized Representatives
Manner of representation
If the management board is a one-person management board, the sole member of the management board is authorized to represent the company. If the management board is a multi-member management board, each member of the management board is authorized to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Wołodymyr Hołubka age 55 | 100 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-01-10.
80 1020 1055 0000 9702 0466 1361
42 1020 1055 0000 9402 0463 0085
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $299$299 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $185$185 | Prezes Zakładu Ubezpieczeń Społecznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Thinkpro sp. z o.o. | $1,563,264.60 | thinkpro.com.pl | ||
| Atlantic Contract sp. z o.o. sp. k. | $1,372,357.91 | atlanticcontract.com | ||
| TAK Pharma sp. z o.o. | $1,137,298.16 | takpharma.com | ||
| Mahta Intl. sp. z o.o. | $1,100,610.29 | mahta.pl | ||
| Yecopharm sp. z o.o. | $807,703.92 | yecopharm.pl | ||
| Esticon sp. z o.o. | $766,909.68 | esticon.com.pl | ||
| 3mind Solutions sp. z o.o. | $736,183.13 | 3mind-solutions.com | ||
| GJ Pharma sp. z o.o. | $551,137.15 | gjpharma.pl | ||
| Pharmalogics sp. z o.o. | $540,258.50 | pharmalogics.pl | ||
| Medis Poland sp. z o.o. | $487,846.47 | medis.com |
FAQ
Last updated: 2026-10-07